Discriminating Alzheimer's disease progression using a new hippocampal marker from T1-weighted MRI: The local surface roughness.


Journal

Human brain mapping
ISSN: 1097-0193
Titre abrégé: Hum Brain Mapp
Pays: United States
ID NLM: 9419065

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 22 10 2018
accepted: 07 11 2018
pubmed: 20 11 2018
medline: 9 4 2020
entrez: 20 11 2018
Statut: ppublish

Résumé

Hippocampal atrophy is one of the main hallmarks of Alzheimer's disease (AD). However, there is still controversy about whether this sign is a robust finding during the early stages of the disease, such as in mild cognitive impairment (MCI) and subjective cognitive decline (SCD). Considering this background, we proposed a new marker for assessing hippocampal atrophy: the local surface roughness (LSR). We tested this marker in a sample of 307 subjects (normal control (NC) = 70, SCD = 87, MCI = 137, AD = 13). In addition, 97 patients with MCI were followed-up over a 3-year period and classified as stable MCI (sMCI) (n = 61) or progressive MCI (pMCI) (n = 36). We did not find significant differences using traditional markers, such as normalized hippocampal volumes (NHV), between the NC and SCD groups or between the sMCI and pMCI groups. However, with LSR we found significant differences between the sMCI and pMCI groups and a better ability to discriminate between NC and SCD. The classification accuracy of the LSR for NC and SCD was 68.2%, while NHV had a 57.2% accuracy. In addition, the classification accuracy of the LSR for sMCI and pMCI was 74.3%, and NHV had a 68.3% accuracy. Cox proportional hazards models adjusted for age, sex, and education were used to estimate the relative hazard of progression from MCI to AD based on hippocampal markers and conversion times. The LSR marker showed better prediction of conversion to AD than NHV. These results suggest the relevance of considering the LSR as a new hippocampal marker for the AD continuum.

Identifiants

pubmed: 30451343
doi: 10.1002/hbm.24478
pmc: PMC6865478
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1666-1676

Subventions

Organisme : Spanish Ministry of Economy and Competitiveness
ID : IJCI-2016-30662
Pays : International
Organisme : Spanish Ministry of Economy and Competitiveness
ID : PSI2012-38375-C03-01
Pays : International
Organisme : Spanish Ministry of Economy and Competitiveness
ID : PSI2009-14415-C03-01
Pays : International

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Références

J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Brain Topogr. 2015 Sep;28(5):746-759
pubmed: 25370484
Nat Rev Neurol. 2010 Feb;6(2):67-77
pubmed: 20139996
Alzheimers Dement. 2015 Feb;11(2):111-25
pubmed: 25267715
Neuroimage. 2009 Oct 1;47(4):1476-86
pubmed: 19463957
Neuroimage. 2014 Aug 15;97:9-18
pubmed: 24736175
Hum Brain Mapp. 2019 Apr 1;40(5):1666-1676
pubmed: 30451343
Artif Intell Med. 2015 Jun;64(2):117-29
pubmed: 25982908
Neuroimage. 2017 May 1;151:72-80
pubmed: 27012504
Hippocampus. 2009 Jun;19(6):579-87
pubmed: 19437497
Neurology. 2012 Sep 25;79(13):1332-9
pubmed: 22914828
Med Image Anal. 2009 Aug;13(4):543-63
pubmed: 19525140
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S141-50
pubmed: 26402076
J Neuroimaging. 2009 Jan;19(1):37-46
pubmed: 18494772
J Alzheimers Dis. 2016 Mar 5;52(1):133-43
pubmed: 27060953
J Neurosci. 2013 Jan 30;33(5):2147-55
pubmed: 23365250
Hum Brain Mapp. 2015 Jan;36(1):258-87
pubmed: 25181316
Neuroimage. 2012 Aug 15;62(2):911-22
pubmed: 22248580
Hippocampus. 2009 Jun;19(6):572-8
pubmed: 19437498
Neuroimage. 2010 Jul 15;51(4):1345-59
pubmed: 20230901
Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):17-27
pubmed: 22343374
Lancet Neurol. 2007 Aug;6(8):734-46
pubmed: 17616482
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Hum Brain Mapp. 2015 Feb;36(2):463-74
pubmed: 25231681
PLoS One. 2016 Feb 22;11(2):e0138866
pubmed: 26901338
Neuroimage. 2015 Jul 15;115:117-37
pubmed: 25936807
Neurology. 2007 Mar 13;68(11):828-36
pubmed: 17353470
Neuroimage. 2011 Jan 15;54(2):985-91
pubmed: 20832487
Neuroimage. 2011 May 15;56(2):766-81
pubmed: 20542124
Neuroimage. 2008 Apr 1;40(2):583-589
pubmed: 18255315
Neurology. 2006 Sep 12;67(5):834-42
pubmed: 16966547
Hum Brain Mapp. 2002 Nov;17(3):143-55
pubmed: 12391568
Alzheimers Dement. 2010 Jan;6(1):11-24
pubmed: 20129317
Nat Genet. 2012 Apr 15;44(5):552-61
pubmed: 22504417
PLoS One. 2011;6(7):e22193
pubmed: 21829449
PLoS One. 2013 Aug 12;8(8):e71354
pubmed: 23951142
J Psychiatr Res. 1982-1983;17(1):37-49
pubmed: 7183759
Neuroimage. 2002 Oct;17(2):825-41
pubmed: 12377157
Neuroimage. 2005 Apr 15;25(3):783-92
pubmed: 15808979
J Neurosci. 2014 Oct 29;34(44):14551-9
pubmed: 25355209
AJNR Am J Neuroradiol. 2009 Mar;30(3):532-8
pubmed: 19112067
IEEE Trans Med Imaging. 2015 Jun;34(6):1242-61
pubmed: 25532173
Neuroimage. 2004 Oct;23(2):724-38
pubmed: 15488422
Ann Neurol. 1980 May;7(5):486-8
pubmed: 7396427
Neuroimage. 2009 Jul 1;46(3):786-802
pubmed: 19195496
Dement Geriatr Cogn Disord. 2008;26(4):323-9
pubmed: 18841017
Neurology. 2004 Feb 24;62(4):591-600
pubmed: 14981176
Neuroinformatics. 2017 Apr;15(2):165-183
pubmed: 28132187
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Cereb Cortex. 2009 Mar;19(3):497-510
pubmed: 18632739
Neuropsychologia. 2008;46(6):1721-31
pubmed: 18289618
Neurobiol Aging. 2012 Feb;33(2):427.e15-30
pubmed: 21272960
Neuroimage. 2010 May 1;50(4):1427-37
pubmed: 20114082
Neuroimage. 2010 Nov 1;53(2):506-14
pubmed: 20600996
J Alzheimers Dis. 2011;26 Suppl 3:61-75
pubmed: 21971451
Neuroimage. 2010 Aug 1;52(1):109-18
pubmed: 20382238

Auteurs

Carlos Platero (C)

Health Science Technology Group, Universidad Politécnica de Madrid, Madrid, Spain.

María Eugenia López (ME)

Laboratory of Cognitive and Computational Neuroscience UCM-UPM Centre for Biomedical Technology; Department of Experimental Psychology, Psychological Processes and Speech Therapy, Universidad Complutense de Madrid and Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.

María Del Carmen Tobar (MD)

Health Science Technology Group, Universidad Politécnica de Madrid, Madrid, Spain.

Miguel Yus (M)

Radiology Department, San Carlos Clinical Hospital, Madrid, Spain.

Fernando Maestu (F)

Laboratory of Cognitive and Computational Neuroscience UCM-UPM Centre for Biomedical Technology; Department of Experimental Psychology, Psychological Processes and Speech Therapy, Universidad Complutense de Madrid and Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH